Tagesspiegel features us

The COVID-19 pandemic has highlighted the urgent need for antiviral agents, generating significant interest in related research. Tagesspiegel.de hits this spot by discussing the MucBoost research project, involving multiple partners and focusing on our new antiviral mechanism of action in a thorough article. With its extensive reach of 9.2 million unique users per month, tagesspiegel.de plays a crucial role in informing a large readership in the capital region of Germany.